Purple Biotech (PPBT) Retained Earnings (2014 - 2026)

Purple Biotech (PPBT) has reported Retained Earnings for 13 consecutive years, with -$170.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 16.75% year-over-year to -$170.7 million in Q2 2026; TTM through Jun 2026 was -$170.7 million, a 16.75% decrease from a year earlier, with the FY2025 full-year figure at -$171.1 million, down 18.24% from the prior year.
• Retained Earnings was -$170.7 million for Q2 2026 at Purple Biotech, roughly flat from -$171.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$103.2 million in Q1 2022 and troughed at -$171.2 million in Q1 2026.
• A 5-year average of -$138.0 million and a median of -$142.4 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings decreased 22.82% in 2022 and declined 1.82% in 2025, its largest moves.
• Over 5 years, Retained Earnings stood at -$117.6 million in 2022, then dropped by 16.91% to -$137.5 million in 2023, then fell by 5.27% to -$144.7 million in 2024, then slipped by 18.24% to -$171.1 million in 2025, then gained by 0.21% to -$170.7 million in 2026.
• The last three Retained Earnings figures came in at -$170.7 million (Q2 2026), -$171.2 million (Q1 2026), and -$171.1 million (Q4 2025), per Business Quant data.